The CCCTBG was founded by Dr. Michael Ward in 2003 to provide a forum for the development of research projects that benefit from the diverse knowledge, expertise, and advice of the CCCTBG members. The aim is to merge scientific rigour with translational research relevance. Photo: Post Hotel Lake Louise January 2015
Each year at the Critical Care Canada Forum (CCCF) there is a lectureship honouring Mike’s contribution to science. The inaugural lecture in 2009 was delivered by Nobel Laureate Dr. Louis Ignarro.
Dr. Jamie Hutchison has been part of the Canadian Critical Care Translational Biology Group since inception. Dr. Hutchison is also the co-chair of the Paediatric Interest Group. Dr Hutchison is a paediatric Critical Care physician and the director of a senior scientist at the SickKids Hospital in Toronto. His scientific focus is on neurocritical care and brain injury. The 3 main goals of his laboratory are 1) to elucidate the role of leukocyte adhesion to endothelial cells in the cerebral microcirculation following global cerebral ischemia, 2) to determine the role of inhibitor of apoptosis proteins following brain injury and 3) to comprehend the mechanisms of hypothermia therapy following brain injury.
Dr. Fox-Robichaud is an executive member and is actively involved with the CCCTBG. Dr. Fox-Robichaud is a critical care physician and a well established basic scientist. She presently has a laboratory at McMaster University. The ultimate goal of her research is to better understand the pathogenesis of multiple organ dysfunction syndrome, a leading cause of morbidity and mortality in the intensive care unit. In order to do so, she concentrate her research on the response of the liver to different inflammatory stimuli and mediators and on the mechanisms that control leukocyte recruitment to the hepatic microcirculation. She uses both simple models of inflammation induced by a single cytokine or chemokine as well as more complex models such as intra abdominal sepsis. She is also interested in the mechanisms by which certain treatment of critically ill patients may alter inflammation.
Dr. Liaw is an Associate Professor at McMaster University in the Department of Medicine in the Division of Hematology & Thromboembolism. Her research lab is based at the new David Braley Cardiac, Vascular, and Stroke Research Institute. She is also an active member of the Canadian Critical Care Translational Biology Group. Dr. Liaw’s overall research interest is to study the mechanistic links between blood clotting, inflammation and cell death, particularly those associated with the pathophysiology of sepsis and thrombosis. One of her major CIHR-funded research programs over the past several years has focused on basic and translational studies of activated protein C (APC). The Overall goal is the better understand the mechanisms by which recombinant APC therapy improves survival in these patients. She is also interested in the identification and validation of blood biomarkers that may have prognostic value in critically ill patients. Her approach is to integrate lab-based studies with clinical research projects to gain understanding into why vascular dysfunction occurs in critically ill patients.
Dr. Brent Winston is the founder of the Canadian Critical Care Translational Biology Group and has been the president of this group since 1993. He is also an active member of the Canadian Critical Care Trials group. Dr. Winston is a critical care intensivist specialized in respiratory medicine and a member of the department of Critical Care Medicine at the Foothills Hospital in Calgary. On top of is clinical duties, Dr. Winston is also heading a fruitful research laboratory. Dr. Winston’s laboratory is located in the Calvin, Phoebe and Joan Snyder Institute of Infection, Immunity and Infection in Calgary. The laboratory’s current research efforts are aimed at defining TNF-stimulated signal transduction pathways in macrophages, which result in macrophage differentiation and the induction of pro-inflammatory and pro-fibrotic genes. Dr. Winston is particularly interested in TNF-induced IGF-I production in macrophages, TNF-stimulated MEKK1 activation and cytokine-stimulated alternative complement cascade Factor B induction in monocytes/macrophages.